BACKGROUND:Conventional laparoscopic Roux-en-Y gastric bypass (LRYGB) has been the reference standard for bariatric surgery but requires 5-7 trocar incisions. We have developed a new procedure-single-incision transumbilical LRYGB (SITU-LRYGB)-that results in minimal scarring and is more cosmetically acceptable. To compare the surgical results and patient satisfaction between 5-port LRYGB and the novel SITU-LRYGB at a university hospital. METHODS: We performed 5-port or SITU-LRYGB on 140 morbidly obese patients; the patients chose the operation method. We used a novel liver traction method and omega-umbilicoplasty specifically designed for SITU-LRYGB. RESULTS: Before surgery, the patients in the 5-port surgery group were more obese than those in the SITU group (120.8 kg versus 108.9 kg, P = .013). The rate of hypertension was also greater in the former group. The operative time was longer for SITU-LRYGB (101.1 versus 81.1 min, P = .001) without increased intraoperative complications. The total morphine dose for the SITU group seemed to be greater but the difference was not statistically significant. No difference in complications was observed. Postoperatively, the percentage of excess body weight lost the SITU and 5-port surgery groups was 21.2% and 20.9%, 40.4% and 39.4%, 55.0% and 55.2%, 64.8% and 75.2%, and 75.4% and 78.2% at 1, 3, 6, 9, and 12 months, respectively. The SITU-LRYGB patients reported greater satisfaction related to scarring than those who had undergone 5-port surgery (score 4.57 versus 3.96, respectively, P = .005). No patient died. CONCLUSION: Compared with conventional LRYGB, SITU-LRYGB resulted in acceptable complications, the same recovery, comparative weight loss, and better patient satisfaction related to scarring. Copyright Â
RCT Entities:
BACKGROUND: Conventional laparoscopic Roux-en-Y gastric bypass (LRYGB) has been the reference standard for bariatric surgery but requires 5-7 trocar incisions. We have developed a new procedure-single-incision transumbilical LRYGB (SITU-LRYGB)-that results in minimal scarring and is more cosmetically acceptable. To compare the surgical results and patient satisfaction between 5-port LRYGB and the novel SITU-LRYGB at a university hospital. METHODS: We performed 5-port or SITU-LRYGB on 140 morbidly obesepatients; the patients chose the operation method. We used a novel liver traction method and omega-umbilicoplasty specifically designed for SITU-LRYGB. RESULTS: Before surgery, the patients in the 5-port surgery group were more obese than those in the SITU group (120.8 kg versus 108.9 kg, P = .013). The rate of hypertension was also greater in the former group. The operative time was longer for SITU-LRYGB (101.1 versus 81.1 min, P = .001) without increased intraoperative complications. The total morphine dose for the SITU group seemed to be greater but the difference was not statistically significant. No difference in complications was observed. Postoperatively, the percentage of excess body weight lost the SITU and 5-port surgery groups was 21.2% and 20.9%, 40.4% and 39.4%, 55.0% and 55.2%, 64.8% and 75.2%, and 75.4% and 78.2% at 1, 3, 6, 9, and 12 months, respectively. The SITU-LRYGB patients reported greater satisfaction related to scarring than those who had undergone 5-port surgery (score 4.57 versus 3.96, respectively, P = .005). No patient died. CONCLUSION: Compared with conventional LRYGB, SITU-LRYGB resulted in acceptable complications, the same recovery, comparative weight loss, and better patient satisfaction related to scarring. Copyright Â
Authors: Tomasz Rogula; Christopher Daigle; Monica Dua; Hideharu Shimizu; Jonathan Davis; Olga Lavryk; Ali Aminian; Philip Schauer Journal: Obes Surg Date: 2014-07 Impact factor: 4.129
Authors: Salvador Morales-Conde; Mercedes Rubio-Manzanares Dorado; Antonio Barranco; Isaías Alarcón; José Luis Pereira; Pedro Pablo García-Luna; María Socas Journal: Surg Endosc Date: 2013-07-12 Impact factor: 4.584
Authors: Salvador Morales-Conde; Andrea Peeters; Yannick M Meyer; Stavros A Antoniou; Isaías Alarcón Del Agua; Alberto Arezzo; Simone Arolfo; Amir Ben Yehuda; Luigi Boni; Elisa Cassinotti; Giovanni Dapri; Tao Yang; Sofie Fransen; Antonello Forgione; Shahab Hajibandeh; Shahin Hajibandeh; Michele Mazzola; Marco Migliore; Christof Mittermair; Doris Mittermair; Antonio Morandeira-Rivas; Carlos Moreno-Sanz; Andrea Morlacchi; Eran Nizri; Myrthe Nuijts; Jonas Raakow; Francisco M Sánchez-Margallo; Juan A Sánchez-Margallo; Amir Szold; Helmut Weiss; Michael Weiss; Ricardo Zorron; Nicole D Bouvy Journal: Surg Endosc Date: 2019-02-15 Impact factor: 4.584